News
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
1d
Money Talks News on MSNYour Wegovy Access Just Changed: What Patients Need to Know NowNovo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...
Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...
1d
Stocktwits on MSNWegovy for $299? Retail Buzz Erupts As WeightWatchers, Novo Nordisk Expand Obesity Drug PushRetail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results